• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Aging Biology and Novel Targets for Drug Discovery

    Thumbnail
    View/Open
    84671_1.pdf (218.5Kb)
    Author(s)
    Le Couteur, David G
    McLachlan, Andrew J
    Quinn, Ronald J
    Simpson, Stephen J
    de Cabo, Rafael
    Griffith University Author(s)
    Quinn, Ronald J.
    Year published
    2012
    Metadata
    Show full item record
    Abstract
    Despite remarkable technological advances in genetics and drug screening, the discovery of new pharmacotherapies has slowed and new approaches to drug development are needed. Research into the biology of aging is generating many novel targets for drug development that may delay all age-related diseases and be used long term by the entire population. Drugs that successfully delay the aging process will clearly become "blockbusters." To date, the most promising leads have come from studies of the cellular pathways mediating the longevity effects of caloric restriction (CR), particularly target of rapamycin and the sirtuins. ...
    View more >
    Despite remarkable technological advances in genetics and drug screening, the discovery of new pharmacotherapies has slowed and new approaches to drug development are needed. Research into the biology of aging is generating many novel targets for drug development that may delay all age-related diseases and be used long term by the entire population. Drugs that successfully delay the aging process will clearly become "blockbusters." To date, the most promising leads have come from studies of the cellular pathways mediating the longevity effects of caloric restriction (CR), particularly target of rapamycin and the sirtuins. Similar research into pathways governing other hormetic responses that influence aging is likely to yield even more targets. As aging becomes a more attractive target for drug development, there will be increasing demand to develop biomarkers of aging as surrogate outcomes for the testing of the effects of new agents on the aging process.
    View less >
    Journal Title
    Journal of Gerontology: Series A
    Volume
    67A
    Issue
    2
    DOI
    https://doi.org/10.1093/gerona/glr095
    Copyright Statement
    © 2012 Oxford University Press. This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Journals of Gerontology Series A following peer review. The definitive publisher-authenticated version, Aging Biology and Novel Targets for Drug Discovery, Journals of Gerontology Series A, Vol. 67A(2), 2012, pp. 168-174] is available online at: dx.doi.org/10.1093/gerona/glr095.
    Subject
    Medicinal and biomolecular chemistry not elsewhere classified
    Clinical sciences
    Publication URI
    http://hdl.handle.net/10072/51821
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander